- Home
- LGO vs IFRX Comparison
LGO vs IFRX Comparison
Compare LGO & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LGO
- IFRX
- Stock Information
- Founded
- LGO 1988
- IFRX 2007
- Country
- LGO Canada
- IFRX Germany
- Employees
- LGO N/A
- IFRX N/A
- Industry
- LGO
- IFRX Biotechnology: Pharmaceutical Preparations
- Sector
- LGO
- IFRX Health Care
- Exchange
- LGO Nasdaq
- IFRX Nasdaq
- Market Cap
- LGO 95.8M
- IFRX 86.0M
- IPO Year
- LGO 2007
- IFRX 2017
- Fundamental
- Price
- LGO $1.10
- IFRX $1.25
- Analyst Decision
- LGO Strong Buy
- IFRX Strong Buy
- Analyst Count
- LGO 1
- IFRX 5
- Target Price
- LGO $3.70
- IFRX $7.40
- AVG Volume (30 Days)
- LGO 3.2M
- IFRX 1.1M
- Earning Date
- LGO 11-12-2025
- IFRX 11-07-2025
- Dividend Yield
- LGO N/A
- IFRX N/A
- EPS Growth
- LGO N/A
- IFRX N/A
- EPS
- LGO N/A
- IFRX N/A
- Revenue
- LGO $108,526,000.00
- IFRX $191,224.00
- Revenue This Year
- LGO N/A
- IFRX N/A
- Revenue Next Year
- LGO $54.96
- IFRX $1,216.24
- P/E Ratio
- LGO N/A
- IFRX N/A
- Revenue Growth
- LGO N/A
- IFRX 54.36
- 52 Week Low
- LGO $1.04
- IFRX $0.71
- 52 Week High
- LGO $2.70
- IFRX $2.82
- Technical
- Relative Strength Index (RSI)
- LGO 38.17
- IFRX 46.11
- Support Level
- LGO $1.10
- IFRX $1.30
- Resistance Level
- LGO $1.19
- IFRX $1.48
- Average True Range (ATR)
- LGO 0.09
- IFRX 0.15
- MACD
- LGO -0.01
- IFRX -0.02
- Stochastic Oscillator
- LGO 23.53
- IFRX 13.64
About LGO Largo Inc.
Largo Inc is committed to the production and supply of high-quality vanadium products. The company is also focused on the advancement of renewable energy storage solutions through Largo Clean Energy and its vanadium redox flow battery technology. The Company is engaged in the mining, exploration, and development of mineral properties, predominantly in Brazil, through which it produces and supplies vanadium products VPURE Flake, VPURE+ Flake, and VPURE+ Powder. The company has operating segments: sales & trading, mine properties, which generates key revenue, corporate, exploration and evaluation properties, Clean Energy, and Largo Physical Vanadium.
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.